KSQ Therapeutics https://validator.w3.org/feed/docs/rss2.html USP1 Regnase-1 SOCS1 About KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy Michael T. Lotze, MD, FACS Richard Moscicki, MD Anna Truppel-Hartmann KSQ-4279 Partners KSQ-004EX David Darst Platform Jason Bock, PhD KSQ Therapeutics Emerges with $76 Million in Financing to Pioneer High-Confidence Drug Development Shari Pilon-Thomas, PhD KSQ Therapeutics Appoints Kristen Hege, M.D., to its Board of Directors KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors Chantale Bernatchez, PhD Michal Besser, PhD KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD 1 Resistant Solid Tumors CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology Kristen Hege, MD Pipeline KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine SITC Poster Presentation: “An Immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets” KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs KSQ Therapeutics Announces Discovery of Gene Targets with Potential Activity Superior to PD-1 for Development of Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapies for Solid Tumors ASGCT Poster Presentation: “Systematic identification of potent guide RNAs with minimal off-target activity for the CRISPR/Cas9 engineering of KSQ-001, and engineered Tumor Infiltrating Lymphocyte (eTIL™)” News AACR Poster Presentation: “KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapy for Solid Tumors KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics KSQ® Therapeutics Presents First Preclinical Data for KSQ-4279, a Novel USP1 Inhibitor, for the Treatment of BRCA-Deficient Cancers KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies KSQ® Therapeutics Appoints Qasim Rizvi, MB ChB., M.B.A., as Chief Executive Officer KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors KSQ Therapeutics Strengthens Leadership Team with Promotion of Micah Benson, Ph.D., to Senior Vice President, Head of Immunobiology and Andrew Wylie, Ph.D., to Senior Vice President, Head of Oncology KSQ Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference KSQ Therapeutics Appoints Chris Heberlig as Chief Financial Officer KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors KSQ Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy 2021 SITC Poster SITC Poster Presentation: “Development of KSQ-001, an Engineered TIL (eTIL®) Therapy for Solid Tumors through CRISPR/Cas9-mediated Inactivation of SOCS1” Home KSQ Therapeutics to Participate in Upcoming Investor Conferences John Lepore, MD KSQ-001EX